Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Plasma-Derived Therapies Market Segmentation
1.Executive Summary
2.Global Plasma-Derived Therapies Market Introduction
2.1.Global Plasma-Derived Therapies Market - Taxonomy
2.2.Global Plasma-Derived Therapies Market - Definitions
2.2.1.By Product
2.2.2.By Disease / Medical Condition
2.2.3.By Region
3.Global Plasma-Derived Therapies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Plasma-Derived Therapies Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Plasma-Derived Therapies Market By Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Intravenous Immunoglobulin (IVIG)
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Clotting Factors Concentrates
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Protein C Concentrates
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Albumin
5.4.1.Albumin Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Factor VIII and IX
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Alpha-1 Antitrypsin (AAT)
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Hyperimmune Globulins
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Fibrinogen Concentrate
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Pooled Plasma Products
5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
5.10. Anti-Thymocyte Globulin (ATG)
5.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.10.3. Market Opportunity Analysis
5.11. Rho(D) Immune Globulin (RhIg)
5.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.11.3. Market Opportunity Analysis
5.12. Varicella-Zoster Immune Globulin (VZIG)
5.12.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.12.3. Market Opportunity Analysis
5.13. Tetanus Immune Globulin (TIG)
5.13.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.13.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.13.3. Market Opportunity Analysis
5.14. Others
5.14.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.14.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.14.3. Market Opportunity Analysis
6.Global Plasma-Derived Therapies Market By Disease / Medical Condition, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Immune Deficiencies
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Hemophilia and Bleeding Disorders
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Autoimmune Disorders
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Alpha-1 Antitrypsin (AAT) Deficiency
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Rabies Post-Exposure Prophylaxis
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Tetanus Prevention
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Cytomegalovirus Prevention in Transplant Recipients
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Varicella-Zoster Virus Prevention
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Hepatitis B Prevention
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Others
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
7.Global Plasma-Derived Therapies Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8.North America Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1.Intravenous Immunoglobulin (IVIG)
8.1.2.Clotting Factors Concentrates
8.1.3.Protein C Concentrates
8.1.4.Albumin
8.1.5.Factor VIII and IX
8.1.6.Alpha-1 Antitrypsin (AAT)
8.1.7.Hyperimmune Globulins
8.1.8.Fibrinogen Concentrate
8.1.9.Pooled Plasma Products
8.1.10.Anti-Thymocyte Globulin (ATG)
8.1.11.Rho(D) Immune Globulin (RhIg)
8.1.12.Varicella-Zoster Immune Globulin (VZIG)
8.1.13. Tetanus Immune Globulin (TIG)
8.1.14 Others
8.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1.Immune Deficiencies
8.2.2.Hemophilia and Bleeding Disorders
8.2.3.Autoimmune Disorders
8.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
8.2.5.Rabies Post-Exposure Prophylaxis
8.2.6.Tetanus Prevention
8.2.7.Cytomegalovirus Prevention in Transplant Recipients
8.2.8.Varicella-Zoster Virus Prevention
8.2.9.Hepatitis B Prevention
8.2.10.Others
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Intravenous Immunoglobulin (IVIG)
9.1.2.Clotting Factors Concentrates
9.1.3.Protein C Concentrates
9.1.4.Albumin
9.1.5.Factor VIII and IX
9.1.6.Alpha-1 Antitrypsin (AAT)
9.1.7.Hyperimmune Globulins
9.1.8.Fibrinogen Concentrate
9.1.9.Pooled Plasma Products
9.1.10.Anti-Thymocyte Globulin (ATG)
9.1.11.Rho(D) Immune Globulin (RhIg)
9.1.12.Varicella-Zoster Immune Globulin (VZIG)
9.1.13. Tetanus Immune Globulin (TIG)
9.1.14 Others
9.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Immune Deficiencies
9.2.2.Hemophilia and Bleeding Disorders
9.2.3.Autoimmune Disorders
9.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
9.2.5.Rabies Post-Exposure Prophylaxis
9.2.6.Tetanus Prevention
9.2.7.Cytomegalovirus Prevention in Transplant Recipients
9.2.8.Varicella-Zoster Virus Prevention
9.2.9.Hepatitis B Prevention
9.2.10.Others
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Intravenous Immunoglobulin (IVIG)
10.1.2.Clotting Factors Concentrates
10.1.3.Protein C Concentrates
10.1.4.Albumin
10.1.5.Factor VIII and IX
10.1.6.Alpha-1 Antitrypsin (AAT)
10.1.7.Hyperimmune Globulins
10.1.8.Fibrinogen Concentrate
10.1.9.Pooled Plasma Products
10.1.10.Anti-Thymocyte Globulin (ATG)
10.1.11.Rho(D) Immune Globulin (RhIg)
10.1.12.Varicella-Zoster Immune Globulin (VZIG)
10.1.13. Tetanus Immune Globulin (TIG)
10.1.14 Others
10.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Immune Deficiencies
10.2.2.Hemophilia and Bleeding Disorders
10.2.3.Autoimmune Disorders
10.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
10.2.5.Rabies Post-Exposure Prophylaxis
10.2.6.Tetanus Prevention
10.2.7.Cytomegalovirus Prevention in Transplant Recipients
10.2.8.Varicella-Zoster Virus Prevention
10.2.9.Hepatitis B Prevention
10.2.10.Others
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Latin America Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Intravenous Immunoglobulin (IVIG)
11.1.2.Clotting Factors Concentrates
11.1.3.Protein C Concentrates
11.1.4.Albumin
11.1.5.Factor VIII and IX
11.1.6.Alpha-1 Antitrypsin (AAT)
11.1.7.Hyperimmune Globulins
11.1.8.Fibrinogen Concentrate
11.1.9.Pooled Plasma Products
11.1.10.Anti-Thymocyte Globulin (ATG)
11.1.11.Rho(D) Immune Globulin (RhIg)
11.1.12.Varicella-Zoster Immune Globulin (VZIG)
11.1.13. Tetanus Immune Globulin (TIG)
11.1.14 Others
11.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Immune Deficiencies
11.2.2.Hemophilia and Bleeding Disorders
11.2.3.Autoimmune Disorders
11.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
11.2.5.Rabies Post-Exposure Prophylaxis
11.2.6.Tetanus Prevention
11.2.7.Cytomegalovirus Prevention in Transplant Recipients
11.2.8.Varicella-Zoster Virus Prevention
11.2.9.Hepatitis B Prevention
11.2.10.Others
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Brazil
11.3.2.Mexico
11.3.3.Rest of LA
12.Middle East and Africa Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Intravenous Immunoglobulin (IVIG)
12.1.2.Clotting Factors Concentrates
12.1.3.Protein C Concentrates
12.1.4.Albumin
12.1.5.Factor VIII and IX
12.1.6.Alpha-1 Antitrypsin (AAT)
12.1.7.Hyperimmune Globulins
12.1.8.Fibrinogen Concentrate
12.1.9.Pooled Plasma Products
12.1.10.Anti-Thymocyte Globulin (ATG)
12.1.11.Rho(D) Immune Globulin (RhIg)
12.1.12.Varicella-Zoster Immune Globulin (VZIG)
12.1.13. Tetanus Immune Globulin (TIG)
12.1.14 Others
12.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Immune Deficiencies
12.2.2.Hemophilia and Bleeding Disorders
12.2.3.Autoimmune Disorders
12.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
12.2.5.Rabies Post-Exposure Prophylaxis
12.2.6.Tetanus Prevention
12.2.7.Cytomegalovirus Prevention in Transplant Recipients
12.2.8.Varicella-Zoster Virus Prevention
12.2.9.Hepatitis B Prevention
12.2.10.Others
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.GCC Countries
12.3.2.South Africa
12.3.3.Rest of MEA
13. Competition Landscape
13.1. Market Player Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
13.2.1.Takeda Pharmaceutical Company
13.2.2.Grifols
13.2.3.CSL Behring
13.2.4.Octapharma
13.2.5.Bio Products Laboratory (BPL)
13.2.6.Kedrion Biopharma
13.2.7.Biotest
13.2.8.China Biologic Products
13.2.9.Kamada
13.2.10.LFB Biomedicaments
14. Research Methodology
15. Appendix and Abbreviations
2.Global Plasma-Derived Therapies Market Introduction
2.1.Global Plasma-Derived Therapies Market - Taxonomy
2.2.Global Plasma-Derived Therapies Market - Definitions
2.2.1.By Product
2.2.2.By Disease / Medical Condition
2.2.3.By Region
3.Global Plasma-Derived Therapies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Plasma-Derived Therapies Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Plasma-Derived Therapies Market By Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Intravenous Immunoglobulin (IVIG)
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Clotting Factors Concentrates
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Protein C Concentrates
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Albumin
5.4.1.Albumin Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Factor VIII and IX
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Alpha-1 Antitrypsin (AAT)
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Hyperimmune Globulins
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Fibrinogen Concentrate
5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Pooled Plasma Products
5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
5.10. Anti-Thymocyte Globulin (ATG)
5.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.10.3. Market Opportunity Analysis
5.11. Rho(D) Immune Globulin (RhIg)
5.11.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.11.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.11.3. Market Opportunity Analysis
5.12. Varicella-Zoster Immune Globulin (VZIG)
5.12.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.12.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.12.3. Market Opportunity Analysis
5.13. Tetanus Immune Globulin (TIG)
5.13.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.13.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.13.3. Market Opportunity Analysis
5.14. Others
5.14.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.14.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.14.3. Market Opportunity Analysis
6.Global Plasma-Derived Therapies Market By Disease / Medical Condition, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Immune Deficiencies
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Hemophilia and Bleeding Disorders
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Autoimmune Disorders
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Alpha-1 Antitrypsin (AAT) Deficiency
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Rabies Post-Exposure Prophylaxis
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Tetanus Prevention
6.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis
6.7. Cytomegalovirus Prevention in Transplant Recipients
6.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.7.3. Market Opportunity Analysis
6.8. Varicella-Zoster Virus Prevention
6.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.8.3. Market Opportunity Analysis
6.9. Hepatitis B Prevention
6.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.9.3. Market Opportunity Analysis
6.10. Others
6.10.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.10.3. Market Opportunity Analysis
7.Global Plasma-Derived Therapies Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8.North America Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1.Intravenous Immunoglobulin (IVIG)
8.1.2.Clotting Factors Concentrates
8.1.3.Protein C Concentrates
8.1.4.Albumin
8.1.5.Factor VIII and IX
8.1.6.Alpha-1 Antitrypsin (AAT)
8.1.7.Hyperimmune Globulins
8.1.8.Fibrinogen Concentrate
8.1.9.Pooled Plasma Products
8.1.10.Anti-Thymocyte Globulin (ATG)
8.1.11.Rho(D) Immune Globulin (RhIg)
8.1.12.Varicella-Zoster Immune Globulin (VZIG)
8.1.13. Tetanus Immune Globulin (TIG)
8.1.14 Others
8.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1.Immune Deficiencies
8.2.2.Hemophilia and Bleeding Disorders
8.2.3.Autoimmune Disorders
8.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
8.2.5.Rabies Post-Exposure Prophylaxis
8.2.6.Tetanus Prevention
8.2.7.Cytomegalovirus Prevention in Transplant Recipients
8.2.8.Varicella-Zoster Virus Prevention
8.2.9.Hepatitis B Prevention
8.2.10.Others
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Intravenous Immunoglobulin (IVIG)
9.1.2.Clotting Factors Concentrates
9.1.3.Protein C Concentrates
9.1.4.Albumin
9.1.5.Factor VIII and IX
9.1.6.Alpha-1 Antitrypsin (AAT)
9.1.7.Hyperimmune Globulins
9.1.8.Fibrinogen Concentrate
9.1.9.Pooled Plasma Products
9.1.10.Anti-Thymocyte Globulin (ATG)
9.1.11.Rho(D) Immune Globulin (RhIg)
9.1.12.Varicella-Zoster Immune Globulin (VZIG)
9.1.13. Tetanus Immune Globulin (TIG)
9.1.14 Others
9.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Immune Deficiencies
9.2.2.Hemophilia and Bleeding Disorders
9.2.3.Autoimmune Disorders
9.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
9.2.5.Rabies Post-Exposure Prophylaxis
9.2.6.Tetanus Prevention
9.2.7.Cytomegalovirus Prevention in Transplant Recipients
9.2.8.Varicella-Zoster Virus Prevention
9.2.9.Hepatitis B Prevention
9.2.10.Others
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Intravenous Immunoglobulin (IVIG)
10.1.2.Clotting Factors Concentrates
10.1.3.Protein C Concentrates
10.1.4.Albumin
10.1.5.Factor VIII and IX
10.1.6.Alpha-1 Antitrypsin (AAT)
10.1.7.Hyperimmune Globulins
10.1.8.Fibrinogen Concentrate
10.1.9.Pooled Plasma Products
10.1.10.Anti-Thymocyte Globulin (ATG)
10.1.11.Rho(D) Immune Globulin (RhIg)
10.1.12.Varicella-Zoster Immune Globulin (VZIG)
10.1.13. Tetanus Immune Globulin (TIG)
10.1.14 Others
10.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Immune Deficiencies
10.2.2.Hemophilia and Bleeding Disorders
10.2.3.Autoimmune Disorders
10.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
10.2.5.Rabies Post-Exposure Prophylaxis
10.2.6.Tetanus Prevention
10.2.7.Cytomegalovirus Prevention in Transplant Recipients
10.2.8.Varicella-Zoster Virus Prevention
10.2.9.Hepatitis B Prevention
10.2.10.Others
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Latin America Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Intravenous Immunoglobulin (IVIG)
11.1.2.Clotting Factors Concentrates
11.1.3.Protein C Concentrates
11.1.4.Albumin
11.1.5.Factor VIII and IX
11.1.6.Alpha-1 Antitrypsin (AAT)
11.1.7.Hyperimmune Globulins
11.1.8.Fibrinogen Concentrate
11.1.9.Pooled Plasma Products
11.1.10.Anti-Thymocyte Globulin (ATG)
11.1.11.Rho(D) Immune Globulin (RhIg)
11.1.12.Varicella-Zoster Immune Globulin (VZIG)
11.1.13. Tetanus Immune Globulin (TIG)
11.1.14 Others
11.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Immune Deficiencies
11.2.2.Hemophilia and Bleeding Disorders
11.2.3.Autoimmune Disorders
11.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
11.2.5.Rabies Post-Exposure Prophylaxis
11.2.6.Tetanus Prevention
11.2.7.Cytomegalovirus Prevention in Transplant Recipients
11.2.8.Varicella-Zoster Virus Prevention
11.2.9.Hepatitis B Prevention
11.2.10.Others
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Brazil
11.3.2.Mexico
11.3.3.Rest of LA
12.Middle East and Africa Plasma-Derived Therapies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Intravenous Immunoglobulin (IVIG)
12.1.2.Clotting Factors Concentrates
12.1.3.Protein C Concentrates
12.1.4.Albumin
12.1.5.Factor VIII and IX
12.1.6.Alpha-1 Antitrypsin (AAT)
12.1.7.Hyperimmune Globulins
12.1.8.Fibrinogen Concentrate
12.1.9.Pooled Plasma Products
12.1.10.Anti-Thymocyte Globulin (ATG)
12.1.11.Rho(D) Immune Globulin (RhIg)
12.1.12.Varicella-Zoster Immune Globulin (VZIG)
12.1.13. Tetanus Immune Globulin (TIG)
12.1.14 Others
12.2. Disease / Medical Condition Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Immune Deficiencies
12.2.2.Hemophilia and Bleeding Disorders
12.2.3.Autoimmune Disorders
12.2.4.Alpha-1 Antitrypsin (AAT) Deficiency
12.2.5.Rabies Post-Exposure Prophylaxis
12.2.6.Tetanus Prevention
12.2.7.Cytomegalovirus Prevention in Transplant Recipients
12.2.8.Varicella-Zoster Virus Prevention
12.2.9.Hepatitis B Prevention
12.2.10.Others
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.GCC Countries
12.3.2.South Africa
12.3.3.Rest of MEA
13. Competition Landscape
13.1. Market Player Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
13.2.1.Takeda Pharmaceutical Company
13.2.2.Grifols
13.2.3.CSL Behring
13.2.4.Octapharma
13.2.5.Bio Products Laboratory (BPL)
13.2.6.Kedrion Biopharma
13.2.7.Biotest
13.2.8.China Biologic Products
13.2.9.Kamada
13.2.10.LFB Biomedicaments
14. Research Methodology
15. Appendix and Abbreviations
• Takeda Pharmaceutical Company
• Grifols
• CSL Behring
• Octapharma
• Bio Products Laboratory (BPL)
• Kedrion Biopharma
• Biotest
• China Biologic Products
• Kamada
• LFB Biomedicaments
• Grifols
• CSL Behring
• Octapharma
• Bio Products Laboratory (BPL)
• Kedrion Biopharma
• Biotest
• China Biologic Products
• Kamada
• LFB Biomedicaments